TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25899215

Group type: EXPERIMENTAL
Intervention: Foot-to-knee graduated compression stockings (n = 17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional socks (control group, n = 17)
Number of subjects: 34
Study: 24074269

Group type: EXPERIMENTAL
Intervention: 12-month lifestyle intervention consisting of weekly group participation for six months on nutrition, physical activity, and lifestyle changes, followed by monthly group participation for an additional six months and individual monthly contacts from facilitators during the second six-month phase.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 21415230

Group type: EXPERIMENTAL
Intervention: Advice and exercise plus true acupuncture (AE+TA)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Advice and exercise plus nonpenetrating acupuncture (AE+NPA)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Advice and exercise (AE)
Number of subjects: 352
Study: 19152918

Group type: EXPERIMENTAL
Intervention: Alcohol consumption with audio-visual perturbations
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Stabilometric platform measurements
Number of subjects: 14
Study: 16539754

Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Online tutorial (self-training)
Number of subjects: 50
Study: 10390399

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ), 250 mg/d (Maintenance group)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No CQ (Observation group)
Number of subjects: 23
Study: 8720650

Group type: EXPERIMENTAL
Intervention: Mediation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional adversarial methods
Number of subjects: 0
Study: 1991440

Group type: EXPERIMENTAL
Intervention: Vitamin E 1200 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitamin E 600 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6341338

Group type: EXPERIMENTAL
Intervention: 0.1 ppm nitrogen dioxide (NO2) for 1 hour
Number of subjects: 30

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 30
Study: 31046880

Group type: EXPERIMENTAL
Intervention: Family Diabetes Self-Management Education (DSME)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Standard Diabetes Self-Management Education (DSME)
Number of subjects: 211
Study: 29510792

Group type: EXPERIMENTAL
Intervention: Acetazolamide (AZT)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acetazolamide (AZT) plus CPAP
Number of subjects: 13

Group type: COMPARATOR
Intervention: CPAP alone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All treatment arms (AZT, CPAP, AZT plus CPAP)
Number of subjects: 13
Study: 26537156

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) every 16 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bevacizumab every 4 weeks
Number of subjects: 48
Study: 24576868

Group type: EXPERIMENTAL
Intervention: Prolonged sitting with subsequent 1-h running at 65% V˙O2max (MOD)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Isoenergetic intermittent walking at approximately 25% V˙O2max (LOW)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Prolonged sitting nonexercise control (CON)
Number of subjects: 9
Study: 22894725

Group type: EXPERIMENTAL
Intervention: Pre-bronchodilator FEV₁
Number of subjects: 4484

Group type: EXPERIMENTAL
Intervention: Post-bronchodilator FEV₁
Number of subjects: 4484
Study: 19909301

Group type: EXPERIMENTAL
Intervention: Chemical matricectomy with 10% sodium hydroxide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (patients without diabetes)
Number of subjects: 30
Study: 17662571

Group type: EXPERIMENTAL
Intervention: Lamotrigine (200, 300, or 400 mg daily)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Lamotrigine (up to 400 mg/day)
Number of subjects: 220
Study: 15764621

Group type: EXPERIMENTAL
Intervention: Early discharge rehabilitation service (EDRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 12200905

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation for 6 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 48
Study: 10220625

Group type: EXPERIMENTAL
Intervention: 30 mg TNK-tPA
Number of subjects: 3235

Group type: EXPERIMENTAL
Intervention: 40 mg TNK-tPA
Number of subjects: 3235

Group type: EXPERIMENTAL
Intervention: 50 mg TNK-tPA
Number of subjects: 3235

Group type: EXPERIMENTAL
Intervention: Overall (30 to 50 mg TNK-tPA)
Number of subjects: 3235

Group type: EXPERIMENTAL
Intervention: Patients treated within 6 hours after symptom onset (30 mg TNK-tPA)
Number of subjects: 3235

Group type: EXPERIMENTAL
Intervention: Patients treated within 6 hours after symptom onset (40 mg TNK-tPA)
Number of subjects: 3235
Study: 7603415

Group type: EXPERIMENTAL
Intervention: Active application (AA) using two PEBA cones fixed bilaterally at point 7 heart
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo application (AP) using two PEBA cones fixed on the back of hand
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Active application (AA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo application (AP)
Number of subjects: 6
Study: 31198974

Group type: EXPERIMENTAL
Intervention: Normocapnic hyperpnoea training (15-20 min per day, 5 times a week for 4 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no respiratory muscle training)
Number of subjects: 18
Study: 29166552

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25384080

Group type: COMPARATOR
Intervention: High-dose oxytocin (6 mU/min with increments every 45 min)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intermediate-dose oxytocin (3 mU/min with increments every 45 min)
Number of subjects: 200

Group type: COMPARATOR
Intervention: High-dose oxytocin (6 mU/min with increments every 45 min) in nulliparous women
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intermediate-dose oxytocin (3 mU/min with increments every 45 min) in nulliparous women
Number of subjects: 200

Group type: COMPARATOR
Intervention: High-dose oxytocin (6 mU/min with increments every 45 min) in multiparous women
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intermediate-dose oxytocin (3 mU/min with increments every 45 min) in multiparous women
Number of subjects: 200
Study: 21884018

Group type: EXPERIMENTAL
Intervention: Accelerated infusion of streptokinase (1.5 MU/20 min)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional infusion of streptokinase (1.5 MU/60 min)
Number of subjects: 300
Study: 21531674

Group type: EXPERIMENTAL
Intervention: Relaxation practice
Number of subjects: 49
Study: 19546253

Group type: EXPERIMENTAL
Intervention: Structured re-assessment system at 6 months post-stroke
Number of subjects: 265

Group type: COMPARATOR
Intervention: Existing care
Number of subjects: 265
Study: 17310863

Group type: EXPERIMENTAL
Intervention: 4.5 mg per day of mirtazapine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 mg per day of mirtazapine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15699486

Group type: EXPERIMENTAL
Intervention: anti-CD3 monoclonal antibody (hOKT3gamma1(Ala‐Ala))
Number of subjects: 0
Study: 11341251

Group type: EXPERIMENTAL
Intervention: Exposure to visual disturbance (flicker, glare, and eyestrain) induced by a very bright, stroboscopic light for varying durations
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Longer exposure to the visual disturbance stimulus
Number of subjects: 110

Group type: COMPARATOR
Intervention: Traditional clinical advice to avoid headache triggers
Number of subjects: 110
Study: 9875725

Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketanserin (serotonin-2A antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone (atypical antipsychotic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol (dopamine antagonist, typical antipsychotic)
Number of subjects: 0
Study: 7978432

Group type: EXPERIMENTAL
Intervention: IV propofol (1-2 mg/kg) followed by a propofol infusion (75-100 micrograms.kg-1.min-1)
Number of subjects: 58

Group type: COMPARATOR
Intervention: IV thiopental (1-3 mg/kg) followed by a pentobarbital bolus (2-3 mg/kg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cost analysis of anesthesia services for propofol
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Patient morbidity and technical quality of MRI scans
Number of subjects: 58
Study: 2558622

Group type: EXPERIMENTAL
Intervention: Cicletanine (100 mg/day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cicletanine-enalapril combination (100 mg/day cicletanine + 20 mg/day enalapril)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 72
Study: 1251236

Group type: EXPERIMENTAL
Intervention: Fluoroscopic positioning of nasogastric tubes
Number of subjects: 6

Group type: COMPARATOR
Intervention: Blind placement of nasogastric tubes
Number of subjects: 6
Study: 30422227

Group type: EXPERIMENTAL
Intervention: Cetuximab and Radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28421669

Group type: EXPERIMENTAL
Intervention: Harsh group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kind group
Number of subjects: 0
Study: 25279797

Group type: EXPERIMENTAL
Intervention: DIY whitening (strawberry and baking soda mix)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Conventional whitening modalities (over-the-counter, dentist-dispensed for home use, and in-office whitening)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 120

Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 120
Study: 23510505

Group type: EXPERIMENTAL
Intervention: Evidence based care following admission to specialist wound clinics
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Access to wound management expertise
Number of subjects: 70
Study: 21216851

Group type: COMPARATOR
Intervention: PRED+SAL
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PRED+EXE
Number of subjects: 8
Study: 18642654

Group type: EXPERIMENTAL
Intervention: Hypofractionated CyberKnife stereotactic radiosurgery (CKSRS) with a marginal dose of 1800-2000 cGy/3 fractions, 80 to 89% isodose line (mean 83%), mean 97.9% tumor coverage.
Number of subjects: 21
Study: 17135615

Group type: EXPERIMENTAL
Intervention: High-dose exercise group (40 minutes per day of aerobic exercise)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-dose exercise group (20 minutes per day of aerobic exercise)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-dose exercise group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study: 12653876

Group type: EXPERIMENTAL
Intervention: Intermittent VLCD (2 weeks every third month after initial 16 weeks)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: On-demand VLCD (as needed when body weight passed an individualized cut-off)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: On-demand VLCD (for male completers)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Intermittent VLCD (for male completers)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Both groups (overall cardiovascular risk factors)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Both groups (anthropometric measures, insulin, HDL- and LDL-cholesterol)
Number of subjects: 334
Study: 10732887

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Medical Treatment
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Both Groups
Number of subjects: 1018
Study: 9026268

Group type: EXPERIMENTAL
Intervention: 1 alpha-hydroxy vitamin D3 (0.75 micrograms/day)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 1395074

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cadralazine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 16
Study: 3903572

Group type: EXPERIMENTAL
Intervention: Terbutaline (1 mg) administered from pressurised aerosol through a nebuhaler
Number of subjects: 20

Group type: COMPARATOR
Intervention: Terbutaline (4 mg) as nebulised solution
Number of subjects: 20
Study: 31442335

Group type: EXPERIMENTAL
Intervention: Terbutaline (8 x 0.5 mg daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 30598484

Group type: EXPERIMENTAL
Intervention: iCT‐R (internet-delivered cognitive training for resilience)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Supported online training of an alternative intervention
Number of subjects: 570

Group type: COMPARATOR
Intervention: Training-as-usual
Number of subjects: 570
Study: 27025829

Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg 4 times daily for 7 days
Number of subjects: 401

Group type: COMPARATOR
Intervention: TMP-SMX 320 mg/1600 mg twice daily for 7 days
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 401

Group type: COMPARATOR
Intervention: TMP-SMX
Number of subjects: 401
Study: 24942540

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ‐SC) 162 mg every other week
Number of subjects: 656

Group type: COMPARATOR
Intervention: Subcutaneous placebo (PBO‐SC) every other week
Number of subjects: 656
Study: 22389077

Group type: EXPERIMENTAL
Intervention: d‐methamphetamine (0.42 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20579835

Group type: EXPERIMENTAL
Intervention: 24-hour recall period using MD Anderson Symptom Inventory (MDASI)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Seven-day recall period using MD Anderson Symptom Inventory (MDASI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both recall periods (24-hour and seven-day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Seven-day recall period (patient preference)
Number of subjects: 42
Study: 17852683

Group type: EXPERIMENTAL
Intervention: Short work:rest exercise protocol (6:9 s)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Long work:rest exercise protocol (24:36 s)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Both short and long exercise protocols
Number of subjects: 9
Study: 15223092

Group type: EXPERIMENTAL
Intervention: Active cue-exposure procedure with immediate feedback about physiological arousal after exposure to cocaine-related stimuli
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 81
Study: 11136839

Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg per day)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control (antibiotics ceftazidime and amikacin without G-CSF)
Number of subjects: 210
Study: 9847275

Group type: EXPERIMENTAL
Intervention: Tidal volume (VT) below 10 ml/kg of body weight
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional ventilatory approach with VT at 10 ml/kg or above
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Tidal volume reduction strategy
Number of subjects: 116
Study: 8026282

Group type: EXPERIMENTAL
Intervention: Diet plus twice daily insulin
Number of subjects: 303

Group type: COMPARATOR
Intervention: Diet therapy
Number of subjects: 303
Study: 2511683

Group type: EXPERIMENTAL
Intervention: Prolonged low-dose intravenous nitroglycerin
Number of subjects: 0
Study: 53654

Group type: EXPERIMENTAL
Intervention: Single and multiple agent chemotherapy
Number of subjects: 188

Group type: COMPARATOR
Intervention: No immediate treatment
Number of subjects: 188
Study: 31150799

Group type: EXPERIMENTAL
Intervention: Statin treatment prescribed after baseline visit
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Oral fat tolerance test (OFTT) meal ingestion
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Follow-up visits for plasma TG measurements
Number of subjects: 900
Study: 30177026

Group type: EXPERIMENTAL
Intervention: Artichoke leaf extract (ALE) 1800 mg/d (four tablets) for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 27304659

Group type: EXPERIMENTAL
Intervention: Active management
Number of subjects: 654

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 654
Study: 25424924

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02
Number of subjects: 36

Group type: COMPARATOR
Intervention: RTS,S/saline
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 and RTS,S/AS02
Number of subjects: 36

Group type: COMPARATOR
Intervention: RTS,S/AS and RTS,S/saline
Number of subjects: 36
Study: 23163141

Group type: EXPERIMENTAL
Intervention: SQNYPBF (Shenmai Injection and Sulfotanshinone Sodium Injection, intravenously dripped once daily for 7 days)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (routine therapies including anti-infection, nutrition support, and glucose control with insulin pump)
Number of subjects: 85
Study: 21209497

Group type: EXPERIMENTAL
Intervention: rtACS (repetitive transorbital alternating current stimulation) for 12 days
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Combined drug therapy/rtACS (D/ACS)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group D (conventional drug therapy)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: rtACS (ACS)
Number of subjects: 98
Study: 16675000

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/day for 2 weeks
Number of subjects: 28
Study: 15583361

Group type: EXPERIMENTAL
Intervention: Standard care plus home visits from a nurse, consultation with an exercise specialist and/or nutritionist
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 12021952

Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg b.i.d.
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 10743482

Group type: EXPERIMENTAL
Intervention: Modified milk fat (M)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional milk fat (D)
Number of subjects: 18
Study: 7720850

Group type: EXPERIMENTAL
Intervention: Acculturation and age
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Having a primary sexual partner
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Having more than one sexual partner in the last month
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Perception of being at high STD risk
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Attitude about condoms
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: History of having an STD
Number of subjects: 691
Study: 1789348

Group type: EXPERIMENTAL
Intervention: Psychoelectrostimulation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Hormonal therapy
Number of subjects: 76
Study: 6113353

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (7-day course)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30031018

Group type: EXPERIMENTAL
Intervention: Laparoscopic magnetic sphincter augmentation (MSA)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Double-dose proton pump inhibitors (BID PPI)
Number of subjects: 152
Study: 28424223

Group type: EXPERIMENTAL
Intervention: Low-dose DCB (2-µg/mm2 surface dose of paclitaxel)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Uncoated PTA balloon
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Low-dose DCB
Number of subjects: 294
Study: 25827407

Group type: EXPERIMENTAL
Intervention: Silver containing garment (3.6% w/w) worn for 8 hours during 5 consecutive days
Number of subjects: 30
Study: 24650952

Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg once-daily for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg once-daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22183208

Group type: EXPERIMENTAL
Intervention: 12‐week standard exercise program (moderate‐intensity to high‐intensity activity 3 or more days per week)
Number of subjects: 855

Group type: COMPARATOR
Intervention: Standard antenatal care (control group)
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: 12‐week standard exercise program
Number of subjects: 855
Study: 19793585

Group type: EXPERIMENTAL
Intervention: Cocoa butter cream
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 300
Study: 17686445

Group type: EXPERIMENTAL
Intervention: Gefitinib and Erlotinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin/Gemcitabine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XRCC3 240 Met/Met mutation
Number of subjects: 0
Study: 15848611

Group type: EXPERIMENTAL
Intervention: CsA treatment with FF genotype
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: CsA and Tac treatment
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: CsA treatment with BB genotype
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: bb genotype
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 67
Study: 12017979

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg vecuronium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rocuronium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg rocuronium
Number of subjects: 60
Study: 9460785

Group type: EXPERIMENTAL
Intervention: Soft contact lenses with in-air spherical aberration compensation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard soft contact lenses
Number of subjects: 61
Study: 7605317

Group type: EXPERIMENTAL
Intervention: Brief information sheet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Long information sheet
Number of subjects: 100
Study: 2368894

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous infusion of morphine
Number of subjects: 0
Study: 7004742

Group type: EXPERIMENTAL
Intervention: Captopril 100 mg
Number of subjects: 30
Study: 30922364

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dressings
Number of subjects: 0
Study: 28589217

Group type: EXPERIMENTAL
Intervention: Microperc
Number of subjects: 60

Group type: COMPARATOR
Intervention: RIRS
Number of subjects: 60